US syringe funding ban impedes HIV and hepatitis C prevention
UK maintains the largest HIV epidemic in western Europe
Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure
Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients
National HIV Prevention Conference highlights progress and disparities
